e-SPACE Heart Failure 2022
Published: 19 October 2022
-
Views:
17470
-
Likes:
7
-
Views:
17470
-
Likes:
7
-
Up Next -
33m 44s
-
1h 4m 11sPart 2 | Session 3 Plenary Session 8: New technologies to treat your patients
-
1h 9sPart 2 | Session 4 Plenary Session 9: Comparing European and US recent guidelines
-
46m 45s
-
1h 1m 38s
-
30m 11s
-
1h 1m 4sPart 2 | Session 8 Plenary Session 11: Managing the HF patient with valvular heart disease
-
31m 36s
-
1h 1m 28sPart 2 | Session 10 Plenary Session 12: Managing the patient with worsening and advanced HF
-
1h 1m 14sPart 1 | Session 1 Plenary Session 1: Implementing the 4 foundational therapies in clinical practice John J Atherton, Piotr Ponikowski, Mark Petrie, Gianluigi Savarese, Kieran Docherty
-
32m 48sPart 1 | Session 2 Meet the expert: Emerging evidence across the spectrum of heart failure: new insights from the deliver trial (Supported by an educational grant from AstraZeneca) John JV McMurray, Rudolf A. de Boer
-
1h 22sPart 1 | Session 3 Plenary Session 2: Managing your HF patients with comorbidities (part 1) Yuhui Zhang, David Sim, Giuseppe Rosano, Vijay Chopra, Béla Merkely, A John Camm
-
36m 21sPart 1 | Session 4 Meet the expert: SGLT2 inhibition in patients with HFpEF ‒ a case-based discussion (Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance) Maurizio Volterrani, Anja Sandek
-
29m 54s
-
1h 1m 19sPart 1 | Session 6 Plenary Session 3: Using SGLT2 in your patients: practical considerations Philippe Gabriel Steg, Shelley Zieroth, Milton Packer, Muthiah Vaduganathan, Cecilia Bahit , Subodh Verma
-
41m 26sPart 1 | Session 7 Satellite Symposium: SGLT2 inhibition as foundational heart failure therapy: have we changed our practices? (Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance) Andrew JS Coats, Shelley Zieroth, Stefan Anker, Daniela Tomasoni, Clara Saldarriaga
-
53m 32sPart 1 | Session 8 Plenary Session 4: Managing your HF patients with comorbidities (part 2) Giuseppe Galati, Altamash Y Shaikh, Ewa Jankowska, George L Bakris, Stephan Von Haehling, Javed Butler
-
33m 53sPart 1 | Session 9 Meet the expert: Best practice recommendations for the management of hyperkalemia (Supported by an educational grant from AstraZeneca) Clara Bonanad Lozano
-
34m 37sPart 1 | Session 10 Meet the expert: Hyperkalaemia in patients with heart failure – dreadful side effect or manageable condition? (Supported by an unrestricted educational grant from CSL Vifor) Javed Butler, Ileana L Piña
-
1h 2m 37sPart 1 | Session 11 Plenary Session 5: Managing side effects of HF drugs Mitja Lainscak, Ambarish Pandey, Faiez Zannad, Justin Ezekowitz, Ileana L Piña, Harriette Van Spall
-
37m 5sPart 1 | Session 12 Meet the expert: Sex differences in advanced heart failure Andrew JS Coats, Aditi Nayak
-
1h 1m 4sPart 1 | Session 13 Plenary Session 6: How to manage the obese patient with HF Antonio Ceriello, Naveed Sattar, Stefan Anker, Tammy Lyn Kindel, Andrew JS Coats, Jean-Philippe Minart
Overview
e-SPACE Heart Failure 2022 was the third edition of the annual global online conference on heart failure. Bringing together thought-leaders from across the globe and broadcast over three time-zones – Asia, Europe, and the Americas – e-SPACE Heart Failure 2022 optimised geographical reach whilst delivering both global and regional insight.
Course leadership Prof Stefan Anker (Charité Campus Virchow-Klinikum, Berlin, DE), Dr Javed Butler (Baylor Scott and White Research Institute, Texas, US), Prof Andrew Coats (University of Warwick, Coventry, UK) and Dr Shelley Zieroth (University of Manitoba, Manitoba, CA) lead an interactive programme of plenary sessions, meet the experts, case discussions and industry sponsored sessions focusing on the patient journey.
For the first time, e-SPACE Heart Failure 2022 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
Learning Objectives
- Review the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
- Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
- Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
- Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
- Translate the findings of recent studies and guidelines into optimal patient management in the regional contexts
Target Audience
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Part 1
Day 1
Part 2
Day 2
Faculty Biographies
Vijay Chopra
Senior Director of Clinical Cardiology, Heart Failure and Research
Dr Vijay Chopra is the Senior Director of Clinical Cardiology, Heart Failure and Research in the Heart Failure Programme at the Max Super Specialty Hospital in Saket, New Delhi, India. He is considered a pioneer in preventive cardiology, and has worked extensively in the management of patients with advanced heart disease. He has been principal investigator of numerous international clinical trials.
Dr Chopra's research interests include preventive cardiology, heart failures and advanced heart diseases. He was awarded the Kutumbiah Prize in Clinical Medicine from CMC Vellore in 1972. He founded the Heart Failure Association of India (HFAI), and served as its first president from 2014 - 2019.
Dr Chopra has over 50 publications in peer-reviewed journals.
Dr Vijay Chopra is an Editorial Board member of Cardiac Failure Review and may be contacted
Friedrich Koehler
Head of the Centre for Cardiovascular Telemedicine, Senior Physician at the Medical Department of Cardiology and Angiology
Jasper J Brugts
Heart Failure Cardiologist
Dr Jasper J Brugts is a Heart Failure Cardiologist at Erasmus University Medical Centre, Rotterdam, NL.
He is also a clinical epidemiologist and clinical trialist.
William T Abraham
Professor of Internal Medicine and Chief of the Division of Cardiovascular Medicine
Prof Abraham is a College of Medicine Distinguished Professor. He has been recognized as one of the “Best Doctors in America” for 18 consecutive years.
His research has led to the approval/adoption of new heart failure therapies, including beta-blockers, natriuretic peptides, cardiac resynchronization therapy, ultrafiltration, implantable hemodynamic monitoring, transvenous phrenic nerve stimulation, cardiac contractility modulation, baroreflex activation therapy, and mitral valve repair.
Prof Abraham has authored more than 1,000 original works and has been named a Clarivate Analytics Highly Cited Researcher and one of The World’s Most Influential Scientific Minds.
He received the 2017 Distinguished Scientist Award from the American College of Cardiology.
With his permission, Prof Abraham is contactable here.
